News
John Smaug
- October 10, 2023
Renovaro Biosciences, a Los Angeles-based biotechnology firm, witnessed a rise in its shares on Tuesday following the appointment of two finance industry veterans to its board. The stock surged by 15% to $5.01 during afternoon trading, reflecting a over a quadruple increase in its value over the course of this year.
A Valuable Addition to the Board
Renovaro announced that Leni Boeren and Ruud Hendriks would be joining the board as independent directors in preparation for the proposed combination with artificial intelligence company GEDi Cube. Boeren brings with her an extensive 40-year career in the financial sector, having held positions at Paribas, Rabobank, Amsterdam Exchanges, and Euronext, in addition to serving as chief executive and chair of Robeco Groep. On the other hand, Hendriks boasts a career spanning 35 years, having worked at Goldman Sachs Asset Management and Robeco, as well as providing advisory services to private-equity firm KKR.
Expertise for Advancing Towards Commercialization
Renovaro Chairman Rene Sindlev expressed his enthusiasm for the new additions to the board, stating that their substantial experience in the capital markets and asset management will provide invaluable financial and business expertise as the company progresses towards commercialization.
Our Latest News
DoorDash Expands Grocery Delivery Services
DoorDash adds 100,000 non-restaurant stores to its platform, focuses on long-term partnerships with grocers. Analyst predicts continued market share growth and...
GE's Third-Quarter Earnings Report Frustrates Investors and Reporters
General Electric's third-quarter earnings release frustrates investors and reporters with confusing non-GAAP numbers and lack of consolidated figures. The compa...
Increase in Consumer Bankruptcies Signals Growing Financial Distress
The number of consumer bankruptcies has steadily risen, indicating an alarming increase in financial distress. Experts are concerned about the long-term implica...